Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

BACKGROUND: Two randomized controlled trials (reSURFACE 1 and 2) have demonstrated the effectiveness of tildrakizumab, a high‐affinity, humanized, IgG1κ, anti‐interleukin‐23 monoclonal antibody, for treating moderate‐to‐severe plaque psoriasis in the first 28 weeks. OBJECTIVES: To examine the effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, A., Sofen, H., Papp, K., Gooderham, M., Tyring, S., Zhao, Y., Lowry, S., Mendelsohn, A., Parno, J., Reich, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899626/
https://www.ncbi.nlm.nih.gov/pubmed/31407394
http://dx.doi.org/10.1111/jdv.15862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899626/
https://www.ncbi.nlm.nih.gov/pubmed/31407394
http://dx.doi.org/10.1111/jdv.15862

Ejemplares similares